Sales of St. Jude Medical's CardioMEMS implantable heart failure monitor are lagging behind the firm's recent predictions. The company cites resistance from payers as the main challenge and executives say they are making a major push to educate insurers about the major cost savings the technology provides.
St. Jude Medical Inc. is stepping up efforts to get payers to increase reimbursement for its CardioMEMS implantable heart failure monitor as sales of the system have slowed compared to expectations.
Response from clinicians to the 2014-launched technology, which remotely monitors pulmonary artery pressure of heart failure patients so clinicians can adjustment treatments without hospital readmissions, has been very positive, according...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
